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CCA development in mouse models of Congenital Hepatic Fibrosis/Caroli Disease 
Eleanna Kaffe1, Carlo Spirli1, Luca Fabris2, Massimiliano Cadamuro2, Mario 
Strazzabosco1. 
1) Dept of Internal Medicine, Section of Digestive Diseases, Yale University. 2) 
Dept of Molecular Medicine, University of Padua.  
  
BACKGROUND: Congenital Hepatic Fibrosis (CHF) and Caroli disease (CD) are genetic 
cholangiopathies caused by mutations in the PKHD1 gene. CD/CHF may progress to 
Cholangiocarcinoma (CCA) in about 15% of patients. CCA progress through a multistep 
process which includes the development of precursor lesions of low, intermediate and 
high grade dysplasia. OBJECTIVES: We aimed to investigate the presence of dysplastic 
lesions that could be prone to neoplastic transformation in Pkhd1del4/del4 mouse, an 
orthologous model of CHF/CD. METHODS: Mucous production was examined by Alcian 
blue staining. Ezh2 and YAP expression in biliary cells was evaluated by 
immunofluorescence. The DNA aneuploidy was examined by FACS. Muc13 gene 
expression levels were evaluated by RT-PCR. Thioacetamide (TAA) was administrated 
in the drinking water (300 mg/L). RESULTS: Pkhd1del4/del4 mice, but not the WT controls, 
display an age-dependent increase of mucous production and nuclear YAP expression. 
DNA aneuploidy, Ezh2 expression and Muc13 gene expression (a marker of early stage 
cancer) were detected only in aged (9- 12-months-old) Pkhd1del4/del4 mice, but not in WT.  
Pkhd1del4/del4 mice treated with TAA develop CCA after 6 months, whereas WT controls 
only show ductular reaction and fibrosis. Ezh2, a marker of cell transformation, showed a 
step-wise increased expression from the untreated to TAA treated Pkhd1del4/del4 mice. 
CONCLUSIONS: The cholangiocytes of aged Pkhd1del4/del4 mice show premalignant 
features of dysplasia and have activated YAP. Treatment with TAA accelerated the 
progression to CAA in Pkhd1del4/del4 but not in WT mice, indicating that Pkhd1del4/del4 mice 
are prone to develop CCA, as in human Caroli Disease and could represent an interesting 
model. 
 
